News Update

First Patient Dosed in Phase II Study of NeoImmuneTech’s NT-I7 plus Pembrolizumab in Recurrent Glioblastoma


February 07, 2023 — ROCKVILLE, MD: NeoImmuneTech, Inc. (NIT), a clinical-stage T cell-focused biopharmaceutical company, today announced the first patient dosed (FPD) in the phase II study NIT-120, which is investigating the combination of NT-I7 and pembrolizumab for the treatment of recurrent glioblastoma (GBM).
Glioblastoma is the most common malignant primary brain tumor, and this intractable cancer has a poor prognosis.1 While treatments are currently available, overall survival for patients is still limited. 2 New combination therapies may offer hope to improve these outcomes.
The goal of NIT-120, which is an investigator-initiated trial (IIT), is to evaluate the safety and effectiveness of NT-I7 and pembrolizumab, as well as the overall survival in patients with recurrent GBM. The study has been initiated following impressive results from the NIT-107 phase I clinical trial in newly diagnosed GBM.
Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech, said, “We are delighted to have the first patient participating in study NIT-120, receiving the first cycle of pembrolizumab plus NT-I7, our unique long-acting human IL-7. This promising combination has potential for providing clinical advances in recurrent glioblastoma– a condition that currently has limited treatment options.”
1 Oronsky B, et al. (2021) A Review of Newly Diagnosed Glioblastoma. Front Oncol. 10:574012. doi: 10.3389/fonc.2020.574012
2 Wick W, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.
*** ENDS ***
Media inquiries :